Armata Pharmaceuticals (ARMP) Operating Leases (2019 - 2026)

Armata Pharmaceuticals (ARMP) has 8 years of Operating Leases data on file, last reported at $26.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 4.5% year-over-year to $26.2 million; the trailing twelve-month figure through Mar 2026 stood at $26.2 million (down 4.5% YoY), and the FY2025 full-year result was $26.5 million, down 4.19% from the prior year.
• Operating Leases declined to $26.2 million in Q1 2026, from $26.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $37.2 million in Q2 2022 to a low of $26.2 million in Q1 2026.
• A 5-year average of $29.7 million and a median of $28.2 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases soared 251.66% in 2022 and fell 26.33% in 2023, its largest moves.
• Tracing ARMP's Operating Leases over 5 years: stood at $31.8 million in 2022, then dropped by 10.13% to $28.6 million in 2023, then retreated by 3.11% to $27.7 million in 2024, then fell by 4.19% to $26.5 million in 2025, then retreated by 1.32% to $26.2 million in 2026.
• Business Quant data shows ARMP's Operating Leases at $26.2 million in Q1 2026, $26.5 million in Q4 2025, and $26.8 million in Q3 2025.